Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Intangibles (2018 - 2023)

Sangamo Therapeutics (SGMO) has 8 years of Intangibles data on record, last reported at $51.6 million in Q1 2023.

  • For Q1 2023, Intangibles fell 2.13% year-over-year to $51.6 million; the TTM value through Mar 2023 reached $51.6 million, down 2.13%, while the annual FY2022 figure was $50.7 million, 5.64% down from the prior year.
  • Intangibles reached $51.6 million in Q1 2023 per SGMO's latest filing, up from $50.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $58.1 million in Q4 2020 and bottomed at $46.4 million in Q3 2022.
  • Average Intangibles over 5 years is $53.1 million, with a median of $53.2 million recorded in 2019.
  • Peak YoY movement for Intangibles: grew 9.35% in 2020, then dropped 15.45% in 2022.
  • A 5-year view of Intangibles shows it stood at $53.2 million in 2019, then rose by 9.35% to $58.1 million in 2020, then dropped by 7.51% to $53.8 million in 2021, then decreased by 5.64% to $50.7 million in 2022, then grew by 1.63% to $51.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Intangibles were $51.6 million in Q1 2023, $50.7 million in Q4 2022, and $46.4 million in Q3 2022.